Baseline characteristics of treated patients (entire cohort and separately those with FL)
| Characteristic . | All (N = 33) . | FL (N = 20) . | ||
|---|---|---|---|---|
| N . | % . | N . | % . | |
| Median age, y (range) | 62 (38-84) | 57 (38-67) | ||
| Sex | ||||
| Female | 11 | 33 | 8 | 40 |
| Male | 22 | 67 | 12 | 60 |
| ECOG performance status | ||||
| 0 | 27 | 82 | 17 | 85 |
| 1 | 5 | 15 | 2 | 10 |
| 2 | 1 | 3 | 1 | 5 |
| Lymphoma histology | ||||
| FL | 20 | 61 | ||
| MZL | 7 | 21 | ||
| MCL | 4 | 12 | ||
| SLL | 2 | 6 | ||
| Ann Arbor stage | ||||
| I/II | 4 | 12 | 2 | 10 |
| III/IV | 29 | 88 | 18 | 90 |
| FLIPI (FL, MZL) | ||||
| 0-1 | 13 | 48 | 12 | 60 |
| 2 | 8 | 30 | 4 | 20 |
| ≥3 | 6 | 22 | 4 | 20 |
| MIPI (MCL only) | ||||
| <5.7 | 0 | 0 | ||
| 5.7-6.5 | 2 | 50 | ||
| ≥6.5 | 2 | 50 | ||
| TP53 aberration (SLL only) | 0 | 0 | ||
| FL grade (FL only) | ||||
| 1/2 | 20 | 100 | ||
| 3A | 0 | 0 | ||
| Indication for treatment∗ | ||||
| Bulky disease† | 13 | 39 | 11 | 55 |
| Symptoms | 9 | 27 | 5 | 25 |
| Threatened end-organ | 4 | 12 | 2 | 10 |
| Cytopenia(s) | 4 | 12 | 2 | 10 |
| Disease progression only | 6 | 18 | 4 | 20 |
| Tumor mass ≥7 cm | 9 | 27 | 6 | 30 |
| Extranodal disease | 21 | 64 | 13 | 65 |
| Characteristic . | All (N = 33) . | FL (N = 20) . | ||
|---|---|---|---|---|
| N . | % . | N . | % . | |
| Median age, y (range) | 62 (38-84) | 57 (38-67) | ||
| Sex | ||||
| Female | 11 | 33 | 8 | 40 |
| Male | 22 | 67 | 12 | 60 |
| ECOG performance status | ||||
| 0 | 27 | 82 | 17 | 85 |
| 1 | 5 | 15 | 2 | 10 |
| 2 | 1 | 3 | 1 | 5 |
| Lymphoma histology | ||||
| FL | 20 | 61 | ||
| MZL | 7 | 21 | ||
| MCL | 4 | 12 | ||
| SLL | 2 | 6 | ||
| Ann Arbor stage | ||||
| I/II | 4 | 12 | 2 | 10 |
| III/IV | 29 | 88 | 18 | 90 |
| FLIPI (FL, MZL) | ||||
| 0-1 | 13 | 48 | 12 | 60 |
| 2 | 8 | 30 | 4 | 20 |
| ≥3 | 6 | 22 | 4 | 20 |
| MIPI (MCL only) | ||||
| <5.7 | 0 | 0 | ||
| 5.7-6.5 | 2 | 50 | ||
| ≥6.5 | 2 | 50 | ||
| TP53 aberration (SLL only) | 0 | 0 | ||
| FL grade (FL only) | ||||
| 1/2 | 20 | 100 | ||
| 3A | 0 | 0 | ||
| Indication for treatment∗ | ||||
| Bulky disease† | 13 | 39 | 11 | 55 |
| Symptoms | 9 | 27 | 5 | 25 |
| Threatened end-organ | 4 | 12 | 2 | 10 |
| Cytopenia(s) | 4 | 12 | 2 | 10 |
| Disease progression only | 6 | 18 | 4 | 20 |
| Tumor mass ≥7 cm | 9 | 27 | 6 | 30 |
| Extranodal disease | 21 | 64 | 13 | 65 |
ECOG, Eastern Cooperative Oncology Group; MCL, mantle cell lymphoma; MIPI, Mantle Cell Lymphoma International Prognostic Index; MZL, marginal zone lymphoma; SLL, small lymphocytic lymphoma.
More than 1 indication possible unless indicated.
Bulky disease defined as ≥3 nodal sites, each ≥3 cm and/or any nodal or extranodal tumor ≥7 cm.